The 30-day metric in acute heart failure revisited: Data from IN-HF Outcome, an Italian nationwide cardiology registry

European Journal of Heart Failure

Volumn 17, Issue 10, 2015, Pages 1032-1041

  Di Tano, Giuseppe ^a   De Maria, Renata ^b   Gonzini, Lucio ^c   Aspromonte, Nadia ^d   Di Lenarda, Andrea ^e   Feola, Mauro ^f   Marini, Marco ^g   Milli, Massimo ^h   Misuraca, Gianfranco ⁱ   Mortara, Andrea ^j   Oliva, Fabrizio ^b   Pulignano, Giovanni ^k   Russo, Giulia ^e   Senni, Michele ^l   Tavazzi, Luigi ^m  

^a CREMONA HOSPITAL   (Italy)

^b OSPEDALE NIGUARDA CA GRANDA   (Italy)

^c ANMCO RESEARCH CENTER   (Italy)

^d SAN FILIPPO NERI HOSPITAL   (Italy)

^e UNIVERSITY OF TRIESTE   (Italy)

^f MAGGIORE HOSPITAL   (Italy)

^g Azienda Ospedaliera Umberto I   (Italy)

^h SANTA MARIA ANNUNZIATA HOSPITAL   (Italy)

ⁱ Ospedale dell'Annunziata   (Italy)

^j Policlinico di Monza   (Italy)

^k SAN CAMILLO FORLANINI HOSPITAL   (Italy)

^l PAPA GIOVANNI XXIII HOSPITAL   (Italy)

^m MARIA CECILIA HOSPITAL   (Italy)

more..

Author keywords

30 Day readmission; Acute heart failure; Days alive out of hospital; mortality

Indexed keywords

INOTROPIC AGENT;

ACUTE HEART FAILURE; AGE DISTRIBUTION; AGED; ARTICLE; CARDIOVASCULAR MORTALITY; CAUSE OF DEATH; CONTROLLED STUDY; DATA ANALYSIS; DISEASE EXACERBATION; DISEASE REGISTRY; DRUG USE; FEMALE; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HOSPITAL READMISSION; HUMAN; INCIDENCE; ITALY; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PREDICTION; PRESCRIPTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECURRENT DISEASE; ACUTE DISEASE; CLINICAL TRIAL; HEART FAILURE; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PROGNOSIS; REGISTER; STATISTICS AND NUMERICAL DATA; VERY ELDERLY;

ACUTE DISEASE; AGED; AGED, 80 AND OVER; FEMALE; HEART FAILURE; HUMANS; INCIDENCE; ITALY; MALE; MIDDLE AGED; PATIENT READMISSION; PROGNOSIS; PROSPECTIVE STUDIES; REGISTRIES;

EID: 84945970900     PISSN: 13889842     EISSN: 18790844     Source Type: Journal    
DOI: 10.1002/ejhf.290     Document Type: Article

References (33)

1. Ambrosy AP, Fonarow GC, Butler J, Chioncel O, Greene SJ, Vaduganathan M, Nodari S, Lam CS, Sato N, Shah AN, Gheorghiade M,. The global health and economic burden of hospitalizations for heart failure: lessons learned from hospitalized heart failure registries. J Am Coll Cardiol 2014; 63: 1123-1133.
2. Gheorghiade M, Vaduganathan M, Fonarow GC, Bonow RO,. Rehospitalization for heart failure: problems and perspectives. J Am Coll Cardiol 2013; 61: 391-403.
3. Au AG, McAlister FA, Bakal JA, Ezekowitz J, Kaul P, van Walraven C,. Predicting the risk of unplanned readmission or death within 30 days of discharge after a heart failure hospitalization. Am Heart J 2012; 164: 365-372.
4. Eapen ZJ1, Liang L, Fonarow GC, Heidenreich PA, Curtis LH, Peterson ED, Hernandez AF,. Validated, electronic health record deployable prediction models for assessing patient risk of 30-day rehospitalization and mortality in older heart failure patients. JACC Heart Fail 2013; 1: 245-251.
5. Krumholz HM, Lin Z, Keenan PS, Chen J, Ross JS, Drye EE, Bernheim SM, Wang Y, Bradley EH, Han LF, Normand SL,. Relationship between hospital readmission and mortality rates for patients hospitalized with acute myocardial infarction, heart failure, or pneumonia. JAMA 2013; 309: 587-593.
6. Hammill BG, Curtis LH, Fonarow GC, Heidenreich PA, Yancy CW, Peterson ED, Hernandez AF,. Incremental value of clinical data beyond claims data in predicting 30-day outcomes after heart failure hospitalization. Circ Cardiovasc Qual Outcomes 2011; 4: 60-67.
7. Allen LA, Hernandez AF, O'Connor CM, Felker GM,. End points for clinical trials in acute heart failure syndromes. J Am Coll Cardiol 2009; 53: 2248-2258.
8. Ariti CA, Cleland JG, Pocock SJ, Pfeffer MA, Swedberg K, Granger CB, McMurray JJ, Michelson EL, Ostergren J, Yusuf S,. Days alive and out of hospital and the patient journey in patients with heart failure: insights from the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) program. Am Heart J 2011; 162: 900-906.
9. Oliva F, Mortara A, Cacciatore G, Chinaglia A, Di Lenarda A, Gorini M, Metra M, Senni M, Maggioni AP, Tavazzi L,; IN-HF Outcome Investigators. Acute heart failure patient profiles, management and in-hospital outcome: results of the Italian Registry on Heart Failure Outcome. Eur J Heart Fail 2012; 14: 1208-1217.
10. Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P, Poole-Wilson PA, Strömberg A, van Veldhuisen DJ, Atar D, Hoes AW, Keren A, Mebazaa A, Nieminen M, Priori SG, Swedberg K,; ESC Committee for Practice Guidelines (CPG). ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J 2008; 29: 2388-2442.
11. Barnard J, Rubin DB,. Small sample degrees of freedom with multiple imputation. Biometrika 1999; 86: 948-955.
12. Harrell FE,. Regression Modeling Strategies With Applications to Linear Models, Logistic Regression, and Survival Analysis. New York: Springer-Verlag; 2001.
13. Westert GP, Lagoe RJ, Keskimäki I, Leyland A, Murphy M,. An international study of hospital readmissions and related utilization in Europe and the USA. Health Policy 2002; 61: 269-278.
14. Maggioni AP, Dahlstrom U, Filippatos G, Chioncel O, Crespo Leiro M, Drozdz J, Fruhwald F, Gullestad L, Logeart D, Fabbri G, Urso R, Metra M, Parissis J, Persson H, Ponikowski P, Rauchhaus M, Voors AA, Nielsen OW, Zannad F, Tavazzi L,; Heart Failure Association of the European Society of Cardiology (HFA). EURObservational Research Programme: regional differences and 1-year follow-up results of the Heart Failure Pilot Survey (ESC-HF Pilot). Eur J Heart Fail 2013; 15: 808-17.
15. Bueno H, Ross JS, Wang Y, Chen J, Vidán MT, Normand SL, Curtis JP, Drye EE, Lichtman JH, Keenan PS, Kosiborod M, Krumholz HM,. Trends in length of stay and short- term outcomes among Medicare patients hospitalized for heart failure, 1993-2006. JAMA 2010; 303: 2141-2147.
16. Curtis LH, Greiner MA, Hammill BG, DiMartino LD, Shea AM, Hernandez AF, Fonarow GC,. Representativeness of a national heart failure quality-of-care registry: comparison of OPTIMIZE-HF and non-OPTIMIZE-HF Medicare patients. Circ Cardiovasc Qual Outcomes 2009; 2: 377-384.
17. O'Connor CM, Abraham WT, Albert NM, Clare R, Gattis Stough W, Gheorghiade M, Greenberg BH, Yancy CW, Young JB, Fonarow GC,. Predictors of mortality after discharge in patients hospitalized with heart failure: an analysis from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF). Am Heart J 2008; 156: 662-667.
18. Italian Agency for Regional Health Services. http://95.110.213.190/PNEed13 (23 September 2014).
19. Di Lenarda A, Scherillo M, Maggioni AP, Acquarone N, Ambrosio GB, Annicchiarico M, Bellis P, Bellotti P, De Maria R, Lavecchia R, Lucci D, Mathieu G, Opasich C, Porcu M, Tavazzi L, Cafiero M,; TEMISTOCLE Investigators. Current presentation and management of heart failure in cardiology and internal medicine hospital units: a tale of two worlds-the TEMISTOCLE study. Am Heart J 2003; 146:E12.
20. Biagi P, Gussoni G, Iori I, Nardi R, Mathieu G, Mazzone A, Panuccio D, Scanelli G, Cicatello C, Rinollo C, Muriago M, Galasso D, Bonizzoni E, Vescovo G,; CONFINE Study Group. Clinical profile and predictors of in-hospital outcome in patients with heart failure: the FADOI 'CONFINE' Study. Int J Cardiol 2011; 152: 88-94.
21. O'Connor CM, Miller AB, Blair JE, Konstam MA, Wedge P, Bahit MC, Carson P, Haass M, Hauptman PJ, Metra M, Oren RM, Patten R, Piña I, Roth S, Sackner-Bernstein JD, Traver B, Cook T, Gheorghiade M,; Efficacy of Vasopressin Antagonism in heart FailureOutcome Study with Tolvaptan (EVEREST) investigators. Causes of death and rehospitalization in patients hospitalized with worsening heart failure and reduced left ventricular ejection fraction: results from Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) program. Am Heart J 2010; 159: 841-849.
22. Dharmarajan K, Hsieh AF, Lin Z, Bueno H, Ross JS, Horwitz LI, Barreto-Filho JA, Kim N, Bernheim SM, Suter LG, Drye EE, Krumholz HM,. Diagnoses and timing of 30-day readmissions after hospitalization for heart failure, acute myocardial infarction, or pneumonia. JAMA 2013; 309: 355-363.
23. Heywood JT, Fonarow GC, Costanzo MR, Mathur VS, Wigneswaran JR, Wynne J,; ADHERE Scientific Advisory Committee and Investigators. High prevalence of renal dysfunction and its impact on outcome in 118,465 patients hospitalized with acute decompensated heart failure: a report from the ADHERE database. J Card Fail 2007; 13: 422-430.
24. Cioffi G, Mortara A, Di Lenarda A, Oliva F, Lucci D, Senni M, Cacciatore G, Chinaglia A, Tarantini L, Metra M, Maggioni AP, Tavazzi; Italian Acute Heart Failure Survey. Clinical features, and in-hospital and 1-year mortalities of patients with acute heart failure and severe renal dysfunction. Data from the Italian Registry IN-HF Outcome. Int J Cardiol 2013; 168: 3691-3697.
25. Greene SJ, 1, Gheorghiade M, Vaduganathan M, Ambrosy AP, Mentz RJ, Subacius H, Maggioni AP, Nodari S, Konstam MA, Butler J, Filippatos G,; EVEREST Trial investigators. Haemoconcentration, renal function, and post-discharge outcomes among patients hospitalized for heart failure with reduced ejection fraction: insights from the EVEREST trial. Eur J Heart Fail 2013; 15: 1401-1411.
26. Testani JM, Chen J, McCauley BD, Kimmel SE, Shannon RP,. Potential effects of aggressive decongestion during the treatment of decompensated heart failure on renal function and survival. Circulation 2010; 122: 265-272.
27. Elkayam U, Tasissa G, Binanay C, Stevenson LW, Gheorghiade M, Warnica JW, Young JB, Rayburn BK, Rogers JG, DeMarco T, Leier CV,. Use and impact of inotropes and vasodilator therapy in hospitalized patients with severe heart failure. Am Heart J 2007; 153: 98-104.
28. Mortara A, Oliva F, Metra M, Carbonieri E, Di Lenarda A, Gorini M, Midi P, Senni M, Urso R, Lucci D, Maggioni AP, Tavazzi L,; IN-HF Outcome Investigators. Treatment with inotropes and related prognosis in acute heart failure: Contemporary data from the Italian Network on Heart Failure (IN-HF) Outcome registry. J Heart Lung Transplant 2014; 33: 1056-1065.
29. Kociol RD, Liang Li, Hernandez AF, Curtis LH, Heidenreich PA, Yancy CW, Fonarow GC, Peterson ED,. Are we targeting the right metric for heart failure? Comparison of hospital 30-day readmission rates and total episode of care inpatient days. Am Heart J 2013; 165: 987-994.
30. Eapen ZJ1, Reed SD, Li Y, Kociol RD, Armstrong PW, Starling RC, McMurray JJ, Massie BM, Swedberg K, Ezekowitz JA, Fonarow GC, Teerlink JR, Metra M, Whellan DJ, O'Connor CM, Califf RM, Hernandez AF,. Do countries or hospitals with longer hospital stays for acute heart failure have lower readmission rates? Findings from ASCEND-HF. Circ Heart Fail 2013; 6: 727-732.
31. Cheng RK, Cox M, Neely ML, Heidenreich PA, Bhatt DL, Eapen ZJ, Hernandez AF, Butler J, Yancy CW, Fonarow GC,. Outcomes in patients with heart failure with preserved, borderline, and reduced ejection fraction in the Medicare population. Am Heart J 2014; 168: 721-730.
32. Blum AB, Egorova NN, Sosunov EA, Gelijns AC, DuPree E, Moskowitz AJ, Federman AD, Ascheim DD, Keyhani S,. Impact of socioeconomic status measures on hospital profiling in New York City. Circ Cardiovasc Qual Outcomes 2014; 7: 391-397.
33. Hernandez AF, Greiner MA, Fonarow GC, Hammill BG, Heidenreich PA, Yancy CW, Peterson ED, Curtis LH,. Relationship between early physician follow-up and 30-day readmission among Medicare beneficiaries hospitalized for heart failure. JAMA 2010; 303: 1716-1722.